
Novel DED drops inch closer
Allegro Ophthalmics, a privately held US biopharmaceutical company, has announced that all primary and secondary endpoints of a 64-eye vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met.












